The recent earnings results from Johnson & Johnson $JNJ
were met with a near 2% sell-off on the day. As ever, a lot of
journalists and commentators immediately searched for a negative in the
results or guidance in order to justify the drop. There was nothing
significantly wrong with the results. However, the company's stock looks
fairly valued and it probably needs to surprise the investment
community on the upside in order to move significantly higher in 2014.
The running story with its divisions in 2013 was one of strong pharmaceutical sales, weakening medical device & diagnostics, and moderately growing consumer products. The fourth quarter results stuck to the script, and it's hard to see how things will change much in 2014.
Pharmaceuticals (39.4% of 2013 sales)
Johnson & Johnson's pharmaceutical performance stood out because it had a number of new drugs in early marketing stages, while continuing to generate strong growth with its Remicade (rheumatoid arthritis) treatment.
Johnson & Johnson's pharmaceutical performance stood out because it had a number of new drugs in early marketing stages, while continuing to generate strong growth with its Remicade (rheumatoid arthritis) treatment.
Remicade sales grew by nearly 14% in the fourth
quarter, and generated more than 23% of pharmaceutical sales and over 9%
of total company sales in the quarter. Meanwhile, some of its newer
drugs achieved very strong growth:
Drug | Treatment | Fourth Quarter Sales ($m) | Fourth Quarter Growth |
Stelara | psoriais | 417 | 55% |
Simponi | rheumatoid arthritis | 254 | 40% |
Invega Sustenna | anti-psychotic | 350 | 54% |
Xarelto | anti-coagulant | 271 | n/a |
Zytiga | castration-resistant prostate cancer | 495 | 87.5% |
Together, these fast-growing drugs generated 24.4%
of total pharmaceutical sales in the fourth quarter. Growth should
continue at a strong pace in 2014 as the company's sales reach is
expanded.
However, one potential problem could be Hospira's (NYSE: HSP )
biosimilar for Remicade, called Inflectra. Hospira's drug was approved
by the European Commission in late 2013, and has proved to be
comparable to Remicade in a large-scale trial. Johnson &
Johnson's patent protection for Remicade will run out in most countries
in Europe in February 2015, and in February 2018 in the United States.
Given the importance of Remicade, Hospira's Inflectra could turn out to
be a challenge to Johnson & Johnson in future.
Medical Device & Diagnostics (40% of 2013 sales)
Pharmaceuticals did well, but the medical device & diagnostics division is facing another difficult year. The whole indusrtry has found it tough. Medical device sales are not often seen as economically sensitive, but when the economy is slow patients tend to make fewer visits to the physician. Ultimately, this results in fewer surgical procedures. Throw in a climate of austerity in hospital spending, and the outlook for medical devices looks moderate in mature markets. Indeed, Johnson & Johnson's management outlined on the conference call that surgical lab procedures were "flat over the last 12 months" in the United States.
Pharmaceuticals did well, but the medical device & diagnostics division is facing another difficult year. The whole indusrtry has found it tough. Medical device sales are not often seen as economically sensitive, but when the economy is slow patients tend to make fewer visits to the physician. Ultimately, this results in fewer surgical procedures. Throw in a climate of austerity in hospital spending, and the outlook for medical devices looks moderate in mature markets. Indeed, Johnson & Johnson's management outlined on the conference call that surgical lab procedures were "flat over the last 12 months" in the United States.
Consumer Products (20.6% of 2013 sales)The
2.8% increase in consumer products sales for the fourth quarter was
disappointing to some, but Foolish investors should note four things
about the division.
First, the consumer products division is probably
the most visible of its operations, though it's actually the least
important in terms of sales. Second, it's also the division with the
largest reliance on international markets, and currency effects reduced
sales by a significant amount. In fact, on a constant currency basis,
consumer products sales were up 4.4% in the fourth quarter. Third, the
company achieved its aim of getting 75% of its over-the-counter brands
(previously affected by production problems) back onto the shelves.
Indeed, its U.S. OTC sales rose 21.6% in the fourth quarter. Finally, if
you exclude the effects of the sales of the manual toothbrush (oral
care) and women's sanitary protection (women's health) businesses then
U.S. sales were actually up 10%, with global operational sales growth up
6%.
Johnson & Johnson in 2014
Looking into 2014, investors should focus on three things:
Looking into 2014, investors should focus on three things:
- Acceleration in the economic recovery so medical device sales can pick up inline with an increase in surgical procedures.
- Ongoing development of pharmaceutical sales, and activity to protect future market share for Remicade in Europe.
- An improvement in its international consumer products sales, as they only grew 3.1% operationally in 2013.
Achieving two of the three things should provide
for some upside surprise, and Johnson & Johnson needs it. On current
analyst estimates, it trades on a valuation of 16 times forward
earnings. The company also has only 6% and 7.4% earnings-per-share
growth estimated in the next two years. This makes it look like a fairly
valued stock.